NCT04737928View on ClinicalTrials.gov

Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)

NACompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

April 2, 2018

Primary Completion Date

January 22, 2019

Study Completion Date

January 22, 2019

Conditions
Glaucoma, Primary Open Angle
Interventions
DRUG

Latanoprost

latanoprost 0.05%(one drop, once daily)

DRUG

tafluprost

tafluprost 0.015% (one drop, once daily)

Trial Locations (1)

Unknown

Chi Mei Hospital Liouying Branch, Tainan City

All Listed Sponsors
lead

Santen Pharmaceutical (Taiwan) Co., LTD

INDUSTRY

NCT04737928 - Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution) | Biotech Hunter | Biotech Hunter